Immunologic Factors: all 3,292 studies that test it
Page 10 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.
- A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic LeukemiaCompletedNCT01263704Phase 2Results posted
- Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)TerminatedNCT01253460Phase 2Results posted
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisCompletedNCT01247324Phase 3Results posted
- Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCTCompletedNCT01246206Phase 2Results posted
- Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating AgentsCompletedNCT01246076Phase 2Results posted
- Combination Immunotherapy and Autologous Stem Cell Transplantation for MyelomaCompletedNCT01245673Phase 2Results posted
- Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLLTerminatedNCT01241786Phase 2Results posted
- Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCLCompletedNCT01241734Phase 1/2Results posted
- Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular LymphomaCompletedNCT01234766Phase 2Results posted
- Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell LymphomaCompletedNCT01234467Phase 2Results posted
- A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose ChemotherapyTerminatedNCT01232556Phase 3Results posted
- Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic AnemiaCompletedNCT01231841Phase 2Results posted
- Rituximab for Patients With Relapsed Acute Lymphoblastic LeukemiaTerminatedNCT01230788Not applicableResults posted
- Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host DiseaseTerminatedNCT01226420Phase 2Results posted
- Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)TerminatedNCT01222195Phase 2Results posted
- Study of Everolimus (RAD001) in Combination With LenalidomideCompletedNCT01218555Phase 1Results posted
- Phase 2/3 Study of IGSC, 20% in PIDDCompletedNCT01218438Phase 2/3Results posted
- A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01217957Phase 1/2Results posted
- Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular LymphomaCompletedNCT01216683Phase 2Results posted
- Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01212952Phase 1/2Results posted
- Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)TerminatedNCT01212094Phase 1/2Results posted
- Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid CancerCompletedNCT01208051Phase 1/2Results posted
- Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell MalignanciesCompletedNCT01206777Phase 2Results posted
- A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLLTerminatedNCT01203930Phase 2Results posted
- A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's LymphomaCompletedNCT01200758Phase 3Results posted
- Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)CompletedNCT01199705Phase 3Results posted
- Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT01199575Phase 2Results posted
- Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom MacroglobulinemiaTerminatedNCT01198067Phase 1Results posted
- Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT01197560Phase 2/3Results posted
- A Study of Ocrelizumab in Participants With Primary Progressive Multiple SclerosisCompletedNCT01194570Phase 3Results posted
- A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal BacteriaCompletedNCT01193582Phase 4Results posted
- Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin LymphomaTerminatedNCT01186458Phase 2Results posted
- Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid MalignanciesCompletedNCT01181258Phase 2Results posted
- MEmbranous Nephropathy Trial Of RituximabCompletedNCT01180036Phase 2/3Results posted
- Revlimid in Transfusion Dependent PatientsCompletedNCT01178814Phase 2Results posted
- Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-DependenceCompletedNCT01178281Phase 3Results posted
- Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney TransplantationCompletedNCT01178216Phase 1/2Results posted
- Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple MyelomaCompletedNCT01177735Phase 2Results posted
- Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLLTerminatedNCT01173679Phase 2Results posted
- Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple MyelomaActive, not recruitingNCT01169337Phase 3Results posted
- Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid LeukemiaCompletedNCT01168219Phase 2Results posted
- Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin LymphomaCompletedNCT01165112Phase 1/2Results posted
- Rituximab to Prevent Recurrence of ProteinuriaTerminatedNCT01164098Phase 3Results posted
- Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)CompletedNCT01161628Phase 2Results posted
- Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory MyelomaCompletedNCT01159574Phase 2Results posted
- Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling DonorsCompletedNCT01158118Phase 2Results posted
- Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple MyelomaCompletedNCT01155583Phase 1/2Results posted
- A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular LymphomasCompletedNCT01153971Phase 2Results posted
- Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin LymphomaCompletedNCT01145495Phase 2Results posted
- A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.TerminatedNCT01144403Phase 2Results posted
- A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)CompletedNCT01144364Phase 3Results posted
- Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell TransplantsTerminatedNCT01135537Phase 2Results posted
- Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryActive, not recruitingNCT01134614Phase 2Results posted
- CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)CompletedNCT01134575Phase 2Results posted
- Cetuximab and Lenalidomide in Head and NeckCompletedNCT01133665Phase 2Results posted
- Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDSCompletedNCT01133275Phase 2Results posted
- R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical TrialCompletedNCT01133158Phase 2Results posted
- SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa TherapyCompletedNCT01126541Phase 3Results posted
- Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLLCompletedNCT01125176Phase 2Results posted
- Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to RituximabCompletedNCT01123356Phase 2Results posted
- Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone LymphomaTerminatedNCT01121757Phase 2Results posted
- Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT01118845Phase 2Results posted
- Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell TransplantTerminatedNCT01118013Phase 2Results posted
- Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell TransplantationTerminatedNCT01116232Phase 2Results posted
- Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)CompletedNCT01109004Phase 3Results posted
- Reversing Type 1 Diabetes After it is EstablishedCompletedNCT01106157Phase 1/2Results posted
- Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy InfantsCompletedNCT01098474Phase 2Results posted
- Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem CellsCompletedNCT01097057Phase 2Results posted
- Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)CompletedNCT01096992Phase 1/2Results posted
- Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01093586Phase 2Results posted
- Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate CancerTerminatedNCT01093183Phase 1/2Results posted
- Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)CompletedNCT01086540Phase 2Results posted
- Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT01082939Phase 2Results posted
- Lenalidomide and High-Dose MelphalanCompletedNCT01079936Phase 1/2Results posted
- Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's MacroglobulinemiaTerminatedNCT01078974Phase 1Results posted
- Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaCompletedNCT01076543Phase 1/2Results posted
- Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaCompletedNCT01075321Phase 1/2Results posted
- Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)CompletedNCT01073163Phase 3Results posted
- Tysabri Effects on Cognition and Neurodegeneration in Multiple SclerosisCompletedNCT01071512Not applicableResults posted
- Treatment Interruption of NatalizumabCompletedNCT01071083Phase 2Results posted
- Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT01060384Phase 1/2Results posted
- Bortezomib Plus Rituximab for EBV+ PTLDCompletedNCT01058239Phase 2Results posted
- Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisTerminatedNCT01058005Phase 3Results posted
- Lenalidomide in Treating Patients With AIDS-Associated Kaposi's SarcomaCompletedNCT01057121Phase 1/2Results posted
- Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's LymphomaCompletedNCT01055496Phase 1Results posted
- Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 StudyActive, not recruitingNCT01054196Phase 1/2Results posted
- Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple MyelomaCompletedNCT01054144Phase 2Results posted
- Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cellsTerminatedNCT01050764Phase 1/2Results posted
- Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedNCT01049945Phase 1/2Results posted
- Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic CancerTerminatedNCT01044745Phase 2Results posted
- Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With NeuroblastomaCompletedNCT01041638Phase 3Results posted
- 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)CompletedNCT01038635Phase 1/2Results posted
- Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin LymphomaCompletedNCT01035463Phase 1/2Results posted
- Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent AnemiaTerminatedNCT01034592Phase 1Results posted
- Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCsCompletedNCT01033552Phase 1/2Results posted
- A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.CompletedNCT01031836Phase 2Results posted
- Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin LymphomasCompletedNCT01030900Phase 2Results posted
- Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade LymphomaCompletedNCT01029730Phase 2Results posted
- A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5qCompletedNCT01029262Phase 3Results posted
- Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple MyelomaCompletedNCT01029054Phase 1/2Results posted